Clinical Trials Browser

Interventional × olaparib × Dermatologic × Clear all

Uveal Melanoma

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05482074 2024-01-19

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Phase 2 Withdrawn

Dermatologic

Uveal Melanoma, Melanoma

NCT04633902 2022-12-06

Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

Phase 2 Unknown

41 enrolled

Dermatologic

Melanoma

NCT00516802 2009-05-15

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine

Phase 1 Completed

40 enrolled

Dermatologic

Melanoma Neoplasms

Clinical Trials

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine